Quest Diagnostics (DGX) Set to Release Earnings on Thursday

Quest Diagnostics (NYSE:DGX) will likely be announcing its Q3 2026 results before the market opens on Thursday, October 22nd. Analysts expect Quest Diagnostics to announce earnings of $2.87 per share and revenue of $3.05 billion for the quarter. Quest Diagnostics has set its FY 2026 guidance at 11.050-11.250 EPS. Parties may visit the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Thursday, October 22, 2026 at 8:30 AM ET.

Quest Diagnostics (NYSE:DGX) last issued its earnings results on Thursday, July 23rd. The medical research company reported $3.12 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.82 by $0.30. The company had revenue of $3.04 billion during the quarter, compared to analyst estimates of $2.97 billion. Quest Diagnostics had a net margin of 9.18% and a return on equity of 16.01%. The company’s revenue for the quarter was up 10.2% on a year-over-year basis. During the same quarter last year, the business posted $2.62 EPS. On average, analysts expect Quest Diagnostics to post $11.15 EPS for the current fiscal year and $11.97 EPS for the next fiscal year.

Quest Diagnostics Trading Up 0.9%

Shares of NYSE DGX opened at $236.93 on Wednesday. The company has a debt-to-equity ratio of 0.72, a quick ratio of 1.46 and a current ratio of 1.59. The stock has a market cap of $26.15 billion, a price-to-earnings ratio of 22.08, a PEG ratio of 2.12 and a beta of 0.54. The business has a 50 day simple moving average of $237.34 and a 200 day simple moving average of $216.03. Quest Diagnostics has a 52 week low of $171.18 and a 52 week high of $248.84.

Quest Diagnostics Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 21st. Investors of record on Tuesday, October 6th will be issued a dividend of $0.86 per share. This represents a $3.44 annualized dividend and a dividend yield of 1.5%. The ex-dividend date of this dividend is Tuesday, October 6th. Quest Diagnostics’s dividend payout ratio is currently 36.52%.

Insider Buying and Selling

In other news, SVP Michael E. Prevoznik sold 22,677 shares of the stock in a transaction dated Friday, August 28th. The shares were sold at an average price of $243.11, for a total transaction of $5,513,005.47. Following the completion of the transaction, the senior vice president directly owned 37,557 shares in the company, valued at $9,130,482.27. This represents a 37.65% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO J. E. Davis sold 10,000 shares of the firm’s stock in a transaction that occurred on Tuesday, September 1st. The shares were sold at an average price of $242.72, for a total value of $2,427,200.00. Following the completion of the transaction, the chief executive officer owned 122,423 shares of the company’s stock, valued at approximately $29,714,510.56. This represents a 7.55% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 34,277 shares of company stock valued at $8,316,493. Company insiders own 0.88% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts recently issued reports on the stock. Truist Financial boosted their target price on shares of Quest Diagnostics from $250.00 to $260.00 and gave the stock a “hold” rating in a research report on Monday, September 21st. Argus set a $260.00 target price on Quest Diagnostics in a research report on Wednesday, July 29th. Robert W. Baird lifted their price target on shares of Quest Diagnostics from $236.00 to $255.00 and gave the company a “neutral” rating in a report on Friday, July 24th. Weiss Ratings raised Quest Diagnostics from a “buy (a-)” rating to a “buy (a)” rating in a research note on Tuesday, October 6th. Finally, Wall Street Zen upgraded shares of Quest Diagnostics from a “hold” rating to a “buy” rating in a research report on Tuesday, July 28th. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and six have given a Hold rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $240.58.

Quest Diagnostics Company Profile

Quest Diagnostics Incorporated (NYSE: DGX) is a provider of diagnostic information services. The company performs laboratory testing that helps physicians, hospitals and other healthcare providers diagnose, treat and monitor diseases and health conditions. Its services include routine blood and other specimen testing, pathology, molecular and genetic testing, and specialized diagnostic services.

Quest Diagnostics serves a broad range of customers, including hospitals, physician practices, health plans, employers, government agencies and individual consumers.